ライフサイエンスコーパス: PCV13

1 PCV13 appears highly effective against invasive pneumoco

2 PCV13 effectiveness among 26 case-control sets of childr

3 PCV13 elicited significantly higher IgG responses for PC

4 PCV13 has a significant added benefit over PCV7 in reduc

5 PCV13 has brought greater benefits than we had expected

6 PCV13 immunisation provides a robust strategy for combat

7 PCV13 provides significant protection for most of the va

8 PCV13 reduced IPD across all age groups when used routin

9 PCV13 resulted in lower acquisition and prevalence of NP

10 PCV13 serotype-specific opsonophagocytic activity (OPA)

11 PCV13 serotypes 19A and 3 were still responsible for hal

12 PCV13 serotypes caused 50% of IPD cases in whites aged >

13 PCV13 significantly reduced NP acquisition of the additi

14 PCV13 vaccination of immunocompromised adults may substa

15 PCV13 was rapidly introduced into the Alaska childhood i

16 12, and 24 months after vaccination in 1006 PCV13 recipients and 1005 controls with 3 age-stratified

17 CV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in childhood immunization programs worl

18 By 2009, PCV13 serotypes caused 71% of cases among whites aged <5

19 In 2010, PCV13 replaced PCV7 in the US immunisation schedule.

20 early disappeared in children eligible for 3 PCV13 doses.

21 er protocol analysis population included 881 PCV13 and 873 PCV7 recipients.

22 colonization than PCV7 did for 4 additional PCV13 serotypes, and serotypes 6C and 19F.

23 y PCV7 plus serotype 6A and the 5 additional PCV13 serotypes (5VT : 1, 3, 5, 7F, 19A) decreased by 96

24 15-0.21) for PCV7+6A serotypes, 5 additional PCV13 serotypes, and all-pneumococcal OM, respectively;

25 The number of additional PCV13 serotypes identified decreased by 74% (27 to 7).

26 ion was shown for four of the six additional PCV13 serotypes (vaccine effectiveness for serotype 3 wa

27 tly reduced NP acquisition of the additional PCV13 serotypes 1, 6A, 7F, and 19A; the cross-reacting s

28 , compared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI

29 Among older adults, PCV13 was effective in preventing vaccine-type pneumococ

30 After PCV13 introduction, antibiotic-nonsusceptible IPD decrea

31 responses for 18 serotypes before and after PCV13 immunization.

32 on significantly decreased in children after PCV13 introduction.

33 ars old) were taken before and 28 days after PCV13 booster immunization.

34 IPD rates in both sexes, rates of IPD after PCV13 were still significantly higher in male than in fe

35 IPD incidence in the total population after PCV13's introduction, and a 71% reduction (95% CI, 62%-7

36 otypes in PCV13 declined significantly after PCV13 introduction in all ages (P </= .01), and the inci

37 red serotypes 1, 6B, 7F, and 19F and against PCV13 serotypes 6A and 19A were measured in peripheral b

38 Vaccine effectiveness against PCV13 serotypes was 86.0% (95% CI 75.5 to 92.3), driven

39 geometric mean concentrations (GMCs) against PCV13-included serotypes 1 month after the booster dose

40 veness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95

41 n immunocompetent adults >/=65 years of age, PCV13 elicits significant increases in OPA titers and Ig

42 cant increases in antibody levels across all PCV13 serotypes (GMFR range, 2.99-23.85; 95% confidence

43 in period 1; 13.8% vs 9.7% in period 2) and PCV13-serotype colonization (8.7% vs 5.4% in period 1; 4

44 plementation of PCV7 (in September 2006) and PCV13 (in April 2010) in children aged <2 years (11 hosp

45 Gambia introduced PCV7 in August, 2009, and PCV13 in May, 2011.

46 al conjugate vaccine (PCV7) (2008-2010), and PCV13 (2011-2013) periods were estimated.

47 ibiotic susceptibilities were determined and PCV13 doses for children documented.

48 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to responses in a historic

49 and in the right leg at 3 and 4 months; and PCV13 in the left leg at 2 months, in the right leg at 4

50 Serotype 6A declined in PCV10 and PCV13 counties, whereas serotype 19A increased in PCV10

51 to monitor the further effects of PCV10 and PCV13 vaccination programmes in young children.

52 the introduction of PCV13 alone or PCV10 and PCV13 with the average incidence during the preceding pe

53 t pneumococcal conjugate vaccines (PCV10 and PCV13) induce immunological memory against Streptococcus

54 the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0.53 (95% CI 0.43-0.65) for in

55 and four use the ten-valent PCV (PCV10) and PCV13.

56 inations compared with TIV without PCV13 and PCV13 without TIV, respectively.

57 After 3 vaccine doses, PCV7 and PCV13 failure rates were 0.19/100000 (95% confidence int

58 res of widespread macrolide use and PCV7 and PCV13 introductions on S. pneumoniae were associated wit

59 In this study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed.

60 In Utah, the introduction of PCV7 and PCV13 was associated with rapid increases in serotype di

61 nt pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serotype dynam

62 nt pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in preventing

63 groups demonstrates the success of PCV7 and PCV13.

64 periods were established: pre-PCV, PCV7, and PCV13.

65 subperiods were defined: pre-PCV, PCV7, and PCV13.

66 cted in 98 subjects (13.8%) by any test, and PCV13-associated serotype(s) were identified by UAD in 7

67 Simultaneous TIV and PCV13 administration was associated with higher transien

68 On days 0 to 1, children receiving TIV and PCV13 simultaneously had higher rates (37.6%) of fever (

69 The excess risk of fever after TIV and PCV13 was 20 and 23 per 100 vaccinations compared with T

70 Nasopharyngeal swabs were taken before PCV13 immunization.

71 l estimate [95% IE] 59-68) and IPD caused by PCV13 minus PCV7 serotypes declined by 93% (91-94), by J

72 ll also declined by 12-32% and IPD caused by PCV13 minus PCV7 type IPD declined by 58-72%, depending

73 n of the additional six serotypes covered by PCV13 (4.48 vs 1.40 per 100,000; IRR 0.31, 0.28-0.35).

74 rmine the prevalence of serotypes covered by PCV13 in a cohort of patients with invasive pneumococcal

75 ing from the additional serotypes covered by PCV13.

76 , 64% of infecting serotypes were covered by PCV13.

77 e was based on immunogenicity data comparing PCV13 with the earlier seven-valent formulation.

78 sive pneumococcal disease and 2991 controls; PCV13 serotype cases (217 [30%]) included most commonly

79 The use of 4 different PCV13 immunization schedules in healthy term infants res

80 0 000 copies/mL were enrolled in this 3-dose PCV13 open-label study.

81 A 3-dose PCV13 regimen followed by a booster dose may be required

82 seroprotective antibody levels against each PCV13 pneumococcal serotype at D301.

83 serotypes against which PCV7 has no effect (PCV13 minus PCV7).

84 he group of serotypes not included in either PCV13 or PPV23 were more frequently isolated in patients

85 accine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical mo

86 We explored PCV13's effect in reducing invasive pneumococcal disease

87 Following PCV13 introduction, dual macrolide-resistant IPD decreas

88 linical indications have decreased following PCV13 use, largely related to decreases in serotype 19A

89 eclining serotype 19A IPD isolates following PCV13 introduction.

90 For PCV13-specific serotypes 6A and 19A, the IgG levels and

91 The vaccine effectiveness for PCV13 and PCV7 was lower than predicted by the aggregate

92 Although the point estimate for PCV13 vaccine effectiveness in children infected with HI

93 with high coverage are sparse, with none for PCV13.

94 cited significantly higher IgG responses for PCV13 additional serotypes and serotype 19F, and similar

95 icating substantial indirect protection from PCV13.

96 PD to that which would have been expected if PCV13 had not replaced PCV7.

97 le IPD and cases that would have occurred if PCV13 had not been introduced.

98 Decreases in PCV13-serotype colonization were observed in HIV-uninfec

99 riod, the proportion of isolates included in PCV13 (plus a related serotype) decreased significantly

100 ceptible IPD caused by serotypes included in PCV13 but not in PCV7 decreased from 6.5 to 0.5 per 100

101 ceptible IPD caused by serotypes included in PCV13 but not PCV7 were prevented among children aged <5

102 oss-protection with 6A, which is included in PCV13.

103 for the six additional serotypes included in PCV13.

104 ne dose against the 13 serotypes included in PCV13.

105 e 6C increased in PCV10 counties, but not in PCV13 counties, suggesting cross-protection with 6A, whi

106 icant decrease were serotype 19F, present in PCV13 and PCV7, and serotypes 6A and 19A, present in PCV

107 d PCV7, and serotypes 6A and 19A, present in PCV13 only.

108 n NVTs, excluding 6C, was more pronounced in PCV13 counties.

109 000, with a 68% (95% CI 39-83) reduction in PCV13 serotypes.

110 eater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .5

111 of IPD due to the additional 6 serotypes in PCV13 and to nonvaccine types (NVTs) increased in childr

112 of IPD due to the 6 additional serotypes in PCV13 declined significantly after PCV13 introduction in

113 CV7 serotypes, the 6 additional serotypes in PCV13, and NVTs were 0.3, 2.8, and 4.4 cases/100 000; th

114 gs show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a s

115 r dose 3 leading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (c

116 e and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneu

117 Low-income countries that introduce PCV13 with reasonable coverage can expect modest reducti

118 A (n = 30 [28.6%]) were responsible for most PCV13 failures.

119 Non-PCV13 serotype cases represented 73% of the isolates in

120 invasive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype repla

121 invasive pneumococcal disease caused by non-PCV13 serotypes was 1.62 (1.09-2.42).

122 antibiotic-nonsusceptible IPD caused by non-PCV13 serotypes, no non-PCV13 serotype dominated among a

123 The most common non-PCV13 serotypes for the combined years were 35B (n = 37)

124 A nonsignificant increase in non-PCV13 serotype OM was observed (IRR, 1.07 [95% CI, .72-1

125 le IPD caused by non-PCV13 serotypes, no non-PCV13 serotype dominated among antibiotic-nonsusceptible

126 ldren younger than 5 years, incidence of non-PCV13 serotypes in 2013/14 was higher than in 2012/13 (a

127 The incidence of non-PCV13 serotypes in children aged 2-59 months increased b

128 the pre-PCV13 baseline, the incidence of non-PCV13 serotypes increased (incidence all ages 4.19 vs 5.

129 , and all-pneumococcal OM, respectively; non-PCV13 serotype episodes were not significantly reduced.

130 umococcal vaccine (PCV13) was high, some non-PCV13-emergent serotypes are more prevalent in immunocom

131 IPD due to non-PCV13 serotypes increased by 30% compared with 76% for n

132 ing invasive pneumococcal disease due to non-PCV13 serotypes, particularly in children younger than 5

133 sification of bacteremia episodes due to non-PCV13 serotypes.

134 cells in PhtD-vaccinated adult mice, but not PCV13-vaccinated mice, caused a loss of vaccine-induced

135 tional 11 serotypes covered by PPV23 but not PCV13.

136 were PCV13 serotypes and 27% were PPV23/not PCV13 serotypes.

137 Notably, PCV13 vaccination resulted in higher frequencies of Bmem

138 In all 3 age categories, a single dose of PCV13 elicited OPA titers and IgG concentrations for all

139 igible to have received at least one dose of PCV13; cases had the same eligibility criteria with the

140 ss the effectiveness of two or more doses of PCV13 against invasive pneumococcal disease in children

141 The effectiveness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disea

142 imate of the effectiveness of three doses of PCV13 against radiological pneumonia was an adjusted odd

143 than 5 years in NYC with 1 or more doses of PCV13 increased from 47.8% in 2010 to 89.8% in 2012.

144 93), 55% had previously received <3 doses of PCV13.

145 strated 1 month after each of the 3 doses of PCV13.

146 from 2008 to 2012 to determine the effect of PCV13 on colonization by pneumococcal serotypes.

147 We assessed the effect of PCV13 use on pneumococcus-related admissions to hospital

148 We also investigated the effectiveness of PCV13 using case-control methods between Sept 12, 2011,

149 umococcal OM rates, with near-elimination of PCV13 disease, was observed shortly after PCV7/PCV13 int

150 The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was inv

151 The impact of PCV13 on a number of clinical aspects of pneumococcal pn

152 We assessed the impact of PCV13 on antibiotic-nonsusceptible IPD rates.

153 Our data suggest a strong impact of PCV13 on CAP, pleural effusion, and documented pneumococ

154 network was set up to analyze the impact of PCV13 on CAP.

155 ing a comprehensive picture of the impact of PCV13 on pneumococcal population structure and informing

156 assessed the potential additional impact of PCV13 over PCV7 on reducing ANSP carriage.

157 ed double-blind trial compared the impact of PCV13 versus PCV7 on nasopharyngeal (NP) colonization an

158 es were identified after the introduction of PCV13 (0/35 [0%] before versus 9/43 [20.9%] after; P = 0

159 -May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013-Dec 31, 2014), adjusting for changes

160 ach of the 4 years after the introduction of PCV13 alone or PCV10 and PCV13 with the average incidenc

161 4 years after the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0.53

162 mission before and after the introduction of PCV13 and used a negative binomial multiple regression m

163 cidence before and after the introduction of PCV13 by serotype grouping, age, and race/ethnicity.

164 quently stabilized until the introduction of PCV13 in 2010 when MR-IPD incidence decreased further fr

165 f MDR serotype 35B after the introduction of PCV13 was directly associated with the emergence of ST15

166 After the introduction of PCV13, the number of cases of PM in children remained un

167 d dramatically following the introduction of PCV13, with reductions among all age and racial/ethnic g

168 the first 3 years after the introduction of PCV13.

169 before and 3 years after the introduction of PCV13.

170 nt cause of IPD prior to the introduction of PCV13.

171 of IPD before and after the introduction of PCV13.

172 remained unchanged after the introduction of PCV13.

173 before and 4 years after the introduction of PCV13.

174 The number of PCV13 doses administered to children younger than 5 year

175 sk, clinical characteristics, or outcomes of PCV13 compared to PCV7 vaccine failure.

176 The proportion of PCV13 serotype cases decreased from 54% in 2007-2009 to

177 d with 2007-2009, although the proportion of PCV13 serotypes decreased significantly.

178 Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per

179 infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 sc

180 f PhtD vaccination was compared with that of PCV13.

181 We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the U

182 The observations support the use of PCV13 in this population.

183 restricted the analysis to sites where only PCV13 was used.

184 e given two priming doses of PCV7 (n=126) or PCV13 (n=237) and opsonophagocytic antibody titre from a

185 TIV (7.5%; aRR, 2.69; 95% CI, 1.30-5.60) or PCV13 (9.5%; aRR, 2.67; 95% CI, 1.25-5.66).

186 n, where the 21 counties use either PCV10 or PCV13 (introduced 2009-2010).

187 Infants were immunized with PCV10 or PCV13 at 2, 3, 4, and 11 months of age.

188 nts were randomized (1:1) to receive PCV7 or PCV13 at ages 2, 4, 6, and 12 months; NP swabs were coll

189 Overall, PCV13 serotypes 19A, 3, 7F, and 1 caused 80% of PP.

190 al serotypes contained in the 13-valent PCV (PCV13) but not in PCV7.

191 (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giv

192 was gradually replaced by the 13-valent PCV (PCV13) starting in November 2010.

193 ns of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates in bot

194 neumococcal conjugate vaccines (PCV7, PCV10, PCV13).

195 V13 disease, was observed shortly after PCV7/PCV13 introduction.

196 We aimed at assessing the impact of PCV7/PCV13 sequential introduction on pneumococcal and overal

197 children <3 years following sequential PCV7/PCV13 introduction.

198 al burden until herd immunity from pediatric PCV13 is fully established.

199 from 53.6 to 23.3 per 100000 admissions post PCV13 (P < .0001).

200 from 47.2 to 15.7 per 100000 admissions post PCV13.

201 Post-PCV13 declines in serotype 19A IPD in persons aged <2 ye

202 07-2009), transitional year (2010), and post-PCV13 (2011-2013).

203 Between pre- and post-PCV13 periods, the proportion of CAP patients with a C-r

204 by 16% (2060 to 1725) between pre- and post-PCV13 periods.

205 e defined: pre-PCV13, transitional, and post-PCV13.

206 Reductions in vaccine-type IPD post-PCV13 were inferior to Australian experience with PCV7 a

207 o 6.4 cases per 100000 (2011-2012 mean) post-PCV13.

208 creases in genetic diversity were noted post-PCV13, and lineages associated with antimicrobial nonsus

209 vaccine (January 2000-July 2002) to the post-PCV13 (July 2010-December 2013) period.

210 Three 1-year periods were defined: pre-PCV13, transitional, and post-PCV13.

211 m 21.0 cases per 100000 (2007-2009 mean) pre-PCV13 to 6.4 cases per 100000 (2011-2012 mean) post-PCV1

212 Patients were divided into 3 subgroups: pre-PCV13 (2007-2009), transitional year (2010), and post-PC

213 n July, 2013, and June, 2014, versus the pre-PCV13 and pre-PCV7 baseline.

214 13/14 decreased by 32% compared with the pre-PCV13 baseline (incidence 10.14 per 100,000 in 2008-10 v

215 Compared with the pre-PCV13 baseline, the incidence of non-PCV13 serotypes inc

216 Only 2 years into the US programme, PCV13 significantly reduced residual invasive and non-in

217 To date no randomized PCV13 pediatric trial has included clinical endpoints.

218 hy infants were randomly assigned to receive PCV13 (n = 932) or PCV7 (n = 934) at ages 2, 4, 6, or 12

219 ants were randomly assigned (1:1) to receive PCV13 at 2, 4, and 12 months (2 + 1 schedule) or 3 and 1

220 were randomly assigned (1:1:1:1) to receive PCV13 either at ages 2, 4, and 6 months (2-4-6); at ages

221 Routine PCV13 at ages 50 and 65 years cost $45,100 per QALY comp

222 duction of a vaccine targeting 13 serotypes (PCV13) in 2010 has led to concern that this scenario wil

223 pneumococcal disease included in the study, PCV13 vaccine effectiveness after two doses before age 1

224 INTERPRETATION: Our results indicate that PCV13 in a 2 + 1 schedule is effective for preventing va

225 We show that PCV13 induces a T-dependent immune response in asplenic

226 Our model results showed that PCV13 was associated with significant reductions in hosp

227 nes transmission, these results suggest that PCV13 will provide protection against ANSP disease that

228 The PCV13 contains 6 serotypes not included in the previousl

229 riod (May 12, 2008, to May 11, 2010) and the PCV13 period (Jan 1, 2014, to Dec 31, 2015).

230 2013, were classified as being caused by the PCV13 serotypes against which PCV7 has no effect (PCV13

231 64-91) reduction in serotypes covered by the PCV13 vaccine.

232 es with differing PCV schedules and from the PCV13 era are needed to inform vaccination strategies fo

233 disease caused by serotypes included in the PCV13 decreased by 82.5% (95% CI, -90.0% to -69.3%), inc

234 ococcal disease occurred in 7 persons in the PCV13 group and 28 persons in the placebo group (vaccine

235 ired pneumonia occurred in 33 persons in the PCV13 group and 60 persons in the placebo group (vaccine

236 red pneumonia occurred in 747 persons in the PCV13 group and 787 persons in placebo group (vaccine ef

237 ired pneumonia occurred in 49 persons in the PCV13 group and 90 persons in the placebo group (vaccine

238 antibiotics) was significantly lower in the PCV13 group compared with the PCV7 group; the main serot

239 quencies of PCs and Bmems were higher in the PCV13 group, pre- and postbooster, except for PC frequen

240 , but there were more local reactions in the PCV13 group.

241 by PCV7 + 6A serotypes was decreased; in the PCV13 period, 5VT OM rates decreased, along with an addi

242 e-PCV period to 2.4 (95% CI, 2.2-2.7) in the PCV13 period.

243 crease continues, the maximum benefit of the PCV13 programme in children might already have been achi

244 dence interval) comparing the pre-PCV to the PCV13 period were 0.02 (0.01-0.04), 0.12 (0.08-0.20), an

245 ococcal pneumonia, particularly cases due to PCV13 serotypes.

246 cidence shortly after the shift from PCV7 to PCV13 in the national immunization program.

247 d serious adverse events possibly related to PCV13 (facial diplegia, injection-site erythema and pyre

248 We determined the immune responses to PCV13 before and at 1, 12, and 24 months after vaccinati

249 Adding PPSV23 at age 75 years to PCV13 at ages 50 and 65 years gained 0.00002 QALYs, cost

250 to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4 to 5 years later.

251 he 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-

252 se 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-valent PCV (PCV10) and

253 a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for

254 of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month intervals, a fourth dose 6 months late

255 age, and the pneumococcal conjugate vaccine (PCV13) at 2, 4, and 12 months, all administered to the r

256 he 13-valent pneumococcal conjugate vaccine (PCV13) at the population level is unclear.

257 of 13-valent pneumococcal conjugate vaccine (PCV13) compared with 23-valent pneumococcal polysacchari

258 he 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for use in immunocompr

259 13-valent polysaccharide conjugate vaccine (PCV13) in preventing first episodes of vaccine-type stra

260 of 13-valent pneumococcal conjugate vaccine (PCV13) in this population.

261 to 13-valent pneumococcal conjugate vaccine (PCV13) occurred in June 2010.

262 of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM) in US children is

263 he 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis.

264 he 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased aft

265 a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained

266 he 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

267 0, 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seven-valent vaccine in the USA.

268 lates were a pneumococcal conjugate vaccine (PCV13) serotype.

269 he 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes

270 he 13-valent pneumococcal conjugate vaccine (PCV13) was inferred before licensure from an aggregate c

271 a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine childhood immunizat

272 he 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

273 0, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended in the USA for preve

274 he 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to replace the 7-valent pneumococcal

275 luded in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool

276 of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended for immunocompromised adults in t

277 he 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity increased in children <5 years (D,

278 ng 13-valent pneumococcal conjugate vaccine (PCV13)-associated serotypes.

279 he 13-valent pneumococcal conjugate vaccine (PCV13).

280 alent pneumococcal CRM197-conjugate vaccine (PCV13; age 6/14 weeks and 9 months).

281 with TIV and 13-valent pneumococcal vaccine (PCV13) in children who were 6 to 23 months old.

282 he 13-valent conjugate pneumococcal vaccine (PCV13) was high, some non-PCV13-emergent serotypes are m

283 -3-4 months, 13-valent pneumococcal vaccine (PCV13, CRM-conjugated) at 2-4 months and 1 or 2 meningoc

284 st, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011.

285 A 13-valent vaccine (PCV13) replaced PCV7 in 2010.

286 4, and 36 weeks of age; a 13-valent vaccine (PCV13) replaced PCV7 in 2011.

287 additional impact of the 13-valent vaccine (PCV13).

288 2002 (7-valent [PCV7]) and 2010 (13-valent [PCV13]).

289 ausing IPD in immunocompromised persons were PCV13 serotypes and 27% were PPV23/not PCV13 serotypes.

290 Whereas PCV13 introduction may reduce racial disparities in IPD,

291 with high HIV prevalence was associated with PCV13-serotype colonization reduction, including among u

292 istics, and outcomes of IPD in children with PCV13 and PCV7 vaccine failure.

293 65 years cost $45,100 per QALY compared with PCV13 substituted in current recommendations.

294 UAD identified 6/7 patients with PCV13 serotype bacteremia without misclassification of b

295 South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule.

296 disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease.

297 Vaccination with PCV13 induces anticapsular immunoglobulin G and opsonoph

298 Vaccination with PCV13 led to a greater reduction of S. pneumoniae NP den

299 Compared to PCV10, vaccination with PCV13 was associated with overall similar IgG levels and

300 r 100 vaccinations compared with TIV without PCV13 and PCV13 without TIV, respectively.

301 In children 0-12 years, PCV13-serotype colonization decreased from period 1 to p